Breaks Categories: News

WednesdaySep 21, 2022 12:11 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24,…

Continue Reading

TuesdaySep 20, 2022 1:43 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug development. The milestones were key in moving Cybin’s psychedelic programs from lab to clinic and have enabled the company to discover potential new drug formulations and delivery methods as well as create clinical protocols for psychedelic compounds and support clinical-stage development of CYBN’s proprietary CYB003…

Continue Reading

TuesdaySep 20, 2022 12:25 pm

PsychedelicNewsBreaks – MindSite News Launches Conversation Series on Psychedelic Resurgence for Mental Health and Wellness

MindSite News — the only news site dedicated exclusively to reporting on mental health in America—today announced that it is launching a live public conversation series. Taking place throughout the month of October, the series is designed to engage the public in conversations about psychedelics and mental health. The campaign also aims to raise funds to support MindSite’s nonprofit journalism and ongoing coverage of this important topic. In the live virtual series hosted by MindSite News, founding editor Rob Waters will be in conversation with key thought leaders to examine the psychedelic resurgence and its potential for bringing healing and…

Continue Reading

ThursdaySep 15, 2022 3:04 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting

Silo Pharma (OTCQB: SILOD), a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it will effect a 1-for-50 reverse split of its common stock. Effective at the open of business on Thursday, Sept. 15, 2022, the reverse stock split is in preparation for the planned listing of the company’s securities on the Nasdaq Capital Market (“Nasdaq”). The company’s common stock has begun trading on the OTC Markets system on a split-adjusted basis under the temporary ticker symbol SILOD. The fifth character “D” will remain appended to Silo Pharma’s symbol for 20 business days or…

Continue Reading

MondaySep 12, 2022 1:13 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Participation at H.C. Wainwright 24th Annual Global Investment Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global Investment Conference taking place Sept. 12-14, 2022. Beginning Monday, Sept. 12, interested parties may access FSD Pharma’s on-demand presentation by visiting https://ibn.fm/mPBst, where it will be hosted for 90 days. In addition, the presentation and supporting materials will be available shortly thereafter on the FSD Pharma website within the “For…

Continue Reading

ThursdaySep 08, 2022 11:35 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Present at H.C. Wainwright Annual Global Investment Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that CEO Matt Stang will be participating in the 24th annual H.C. Wainwright Annual Global Investment Conference. The three-day event is scheduled for Sept. 12–14, 2022. During his presentation, Stang will provide a summary of the company’s focus on growing its clinic footprint and accepting a wider selection of insurance options; the presentation will also include Delic’s strategic outlook for the remainder of the year. In addition, Stang will be available for one-on-one meetings throughout the conference. Stang’s presentation will…

Continue Reading

WednesdaySep 07, 2022 11:08 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Makes Top-100 Innovation List, Company Postpones Meet Delic Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Matt Stang was included in World Biz magazine’s Top-100 CEOs in Innovation for 2022. The announcement noted that Stang was recognized as a champion of creativity who is dedicated to making a positive environmental and social impact. Stand cofounded Delic Corp., which has grown into a leader in new medicines and treatments for a modern world. Stang led the company’s acquisition of the Ketamine Wellness Centers, and under his guidance, the company reported more than $1.5 million in total revenue in 2021 while more than quadrupling its net assets. This month, Stang…

Continue Reading

TuesdaySep 06, 2022 12:32 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Secures FDA and Health Canada Approval for Phase 2 Trial of FSD201

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced its receipt of a “Study May Proceed” letter for the Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its phase 2 clinical trial of FSD201. The trial will study the safety and efficacy of FSD201 in patients with chronic widespread musculoskeletal nociplastic pain associated with idiopathic mast cell activation syndrome. “We are delighted to…

Continue Reading

WednesdayAug 31, 2022 12:31 pm

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. “This final development milestone marks the completion of a detailed series of goals set between Cybin and Adelia almost two years ago. Our combined teams have executed…

Continue Reading

TuesdayAug 30, 2022 10:47 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To…

Continue Reading